Introduction
Lifestyle has an important influence on the development of cancer in humans. Diet is one of the most important contributing lifestyle factors. In the 1970s, scientists started to search for mutagens/carcinogens from food in hopes of eventually using this knowledge to help prevent cancer. Dr. Pariza's group was searching for mutagens from cooked ground beef extract in the 1980s. In addition to the fractions with mutagenic activities, they found a fraction with antimutagenic activity (Pariza and Hargraves, 1985) . Later the principal compound was identified as conjugated linoleic acid (CLA) (Ha et al., 1987) . The compound was named CLA based on its structural similarity to linoleic acid. Both have the same chemical formula but CLA has two double bonds conjugated instead of methylene interrupted as in linoleic acid. In fact, CLA refers to a group of geometric and positional isomers of conjugated linoleic acid. The main isomer present in foods, such as meat and dairy products, is the cis-9,trans-11 isomer (Ha et al., 1987 , Chin et al., 1992 . This isomer can be formed during the biohydrogenation of linoleic acid to stearic acid by rumen bacteria (Kepler and Tove, 1967) . Alternatively, latest research shows that it can form in animals via 9 desaturation of trans-11 octadecenoic acid (vaccenic acid) (Palmquist and Santora, 1999; Pollard et al., 1980) . The trans-10,cis-12 CLA isomer is also naturally present, but to a lesser extent (Park and Pariza, 1998) . For experimental purposes, CLA is prepared by alkali isomerization from pure linoleic acid. This preparation contains about 95% CLA, mainly the cis-9, trans-11 and trans-10,cis-12 isomers (85-90%, 40.8-41.1% cis-9,trans-11 and 43.5-44.9% trans-10,cis-12) along with other minor isomers (trans,trans or cis,cis) (Ha et al., 1989) . However, depending on the source of linoleic acid (pure fatty acid or vegetable oil) and conditions of isomerization, the isomer distribution can vary significantly (Christie et al., 1997) . In some studies CLA preparations contain a more complex mixture of isomers, such as 8,10 and 11,13 isomers as well as 9,11 and 10,12 isomers (Christie et al., 1997) .
CLA prepared from pure linoleic acid (CLA-mixture) has shown a wide range of biologically beneficial activities; reduction of carcinogenesis in several animal models (Ha et al., 1987 (Ha et al., , 1990 Ip et al., 1991; Liew et al., 1995) , decreased severity of atherosclerosis (Lee et al., 1994; Nicolosi et al., 1993) , reduction of adverse effects of immune stimulation (Cook et al., 1993; Miller et al., 1994) , growth promotion in young rats (Chin et al., 1994) , and a reduction of body fat and an increase in lean body mass in several animal species (Cook et al., 1998; Houseknecht et al., 1998; Park, 1996; Park et al. 1997 Park et al. , 1999a Park et al. , 1999b . The main isomer present in food, cis-9,trans-11 CLA, has been postulated to be the biologically active isomer, since Ha et al. (1990) reported that only the cis-9,trans-11 isomer was incorporated in the phospholipid fraction of mouse forestomach.
However, recently several investigators (Belury and Kempa-Steczco, 1997; Park, 1996; Sugano et al., 1998) reported that all CLA isomers are incorporated in both phospholipids and neutral lipids. Currently, it is believed that the cis-9,trans-11 CLA isomer is responsible for growth promotion effects , and the trans-10,cis-12 isomer is responsible for body composition changes in mice and the decrease in lipoprotein lipase activity in 3T3-L1 adipocytes (Park et al., 1999b) . Ip et al. (1999 Ip et al. ( , 2000 suggested that both isomers can effectively reduce chemically induced rat mammary neoplasia. In this review, we will focus on the effects of CLA on immune responses, body compositional changes, and stearoylCoA desaturase (SCD).
CLA and Immune Responses
During infection, endotoxin (or lipopolysaccharide, LPS), a cell membrane component of gram negative bacteria, can elicit a series of immune responses in animals. Endotoxin can initiate the secretion of cytokines, especially tumor necrosis factor-alpha (TNF-) and interleukin-1 (IL-1) and these cytokines can cause biochemical changes in other cells (Beutler and Cerami, 1987; Dinarello, 1984) . TNFis reported to be a key mediator in many diseases including cachexia (Beutler and Cerami, 1987; Freeman and Roubenoff, 1994) , inflammation (Lewis, 1983) , carcinogenesis (Okahara et al., 1994; Suganuma et al., 1996) , atherosclerosis (Ross, 1993) , and obesity (Hotamisligil and Spiegelman, 1994) . TNF-receptors are expressed in most cells in the body.
Earlier work showed that CLA feeding reduced the adverse effects of endotoxin by reducing body weight loss and improving food intake in rats, chicks and mice (Cook et al., 1993; Miller et al., 1994) . When animals were injected with TNF-, they developed symptoms similar to those of endotoxin injection (reduced body weight and food intake). CLA feeding significantly reduced these adverse effects of TNF-injection in mice . In addition, CLA treatment reduced the secretion of TNF-when cells were stimulated with LPS, compared to linoleic acid or control in cultured RAW 264.7 macrophage cells.
It has been suggested that the mechanism by which CLA effects the immune response may be through the reduction of prostaglandin E 2 (PGE 2 ), a regulator of TNF-. CLA decreased the levels of arachidonic acid in tissue, which is a major substrate for the formation of PGE 2 . As a result of less arachidonic acid, CLA decreased the level of PGE 2 in serum, spleen, bone, adipose tissue, keratinocytes, and macrophages (Cook et al., 1993; Li and Watkins, 1998; Liu and Belury, 1998; Park et al., 2000a; Sugano et al., 1997) . Recently, Whigham et al. (2000) reported the effect of CLA in type I hypersensitivity model using sensitization of guinea pigs to antigen such as ovalbumin. CLA feeding decreased both cyclooxygenase and lipoxygenase products (TXB 2 , 6keto-PGF 1 , PGF 2 , PGD 2 , PGE 2 , leukotriene C 4 , D 4 , and E 4 ) in lungs and trachea in response to antigen challenge. This suggests that CLA may profoundly effect the modulation of immune responses through an eicosanoid mechanism, especially to TNF-.
The reduced adverse effect of endotoxin or TNF-by CLA was not due to immune suppression because CLA also enhanced some immune responses, for example, delayed type hypersensitivity and lymphocyte blastogenesis (Cook et al., 1993; Miller et al., 1994) . However, others have reported that CLA enhanced T-cell function but had no effect on delayed-type hypersensitivity skin reaction or B cell and Natural Killer cell activity in mice (Hayek et al., 1998) . Kelley et al. (2000) reported on the effect of CLA (as a mixture of cis-9, trans-11, trans-10,cis-12, cis-11,trans-13, and trans-8,cis-10 isomers, about 80%) in young healthy women at a dose of 3.9 g/day for 2 months. In this study, there were no differences in immune parameters tested between the CLA and control groups (i.e. cell number, lymphocyte proliferation, antibody titer and delayed-type hypersensitivity). It is interesting that Visonneau et al. (1997) and Cesano et al. (1998) reported that CLA reduced transplanted tumor growth in severe combined immunodeficient (SCID) mice, which lack T-and B-lymphocytes. This suggests that CLA's anticancer effect may not involve these immune responses. However, they have not completely ruled out the possible involvement of natural killer cells and macrophages in these models.
CLA and Body Composition
One of the most interesting and consistent aspects of CLA is its ability to reduce body fat mass dramatically while increasing lean body mass (Table 1) . This increase in protein (as g value) is small but significant compared to control (P < .05 when 11 mice experiments were pooled, Park et al. 1997) . Similar results were observed in chickens, hamsters, dogs and pigs, (Cook et al., 1998; deDeckere et al., 1999; Dugan et al., 1999; Park, 1996; Schoenherr and Jewell, 1999; Stangl, 2000) , but results are not consistent in rats and humans (Jahreis et al., 2000; Park, 1996) . Out of 9 published human studies, six showed CLA reduced body fat while increasing lean body mass (Berven et al., 2000; Blankson et al., 2000; Jahreis et al., 2000; Zambell et al., 2000) . The fact that not all studies showed a body fat reduction may be due to differences in metabolism of the animal, as proposed recently ). The type of fat (corn, coconut oil or beef tallow) or amount of fat (low or high) that was used did not affect the results in mice (unpublished observation). During these animal experiments, it was observed that CLA decreased feed intake slightly compared to control animals (DeLany et al., 1999; Park et al., 1997 Park et al., , 1999 . However, this reduction of feed intake was relatively small (less than 15 % or no statistical differences in overall feeding periods) compared to the body fat changes (more than 30% reduction compared to control). Therefore, it is unlikely that decreased feed intake was the main cause of reduced body fat. In support of this statement, our recent study with pair-feeding indicated that CLA indeed decreased body fat compared to pair-fed animals as well as controls (manuscript in preparation). Two possible mechanisms have been proposed for the effects of CLA on body compositional changes. First, CLA decreases fat uptake and increases fat release in adipocytes. Secondly, it increases fatty acid -oxidation in muscle. This first conclusion was based on experiments using fully differentiated 3T3-L1 mouse adipocyte models. CLA treatment decreased intracellular triacylglycerol and glycerol and inhibited lipoprotein lipase (LPL) activity in this cell line, which is the major enzyme of fatty acid uptake for storage in adipocytes (Park et al., 1997) . This inhibition was associated with the trans-10,cis-12 isomer of CLA, while cis-9,trans-11 and trans-9,trans-11 isomers of CLA had no effect on this enzyme activity (Park et al., 1999b) . CLA also enhanced lipolysis measured as glycerol release in 3T3-L1 cell, and the trans-10,cis-12 isomer was the most effective isomer in this regard. However, CLA may have a minimum impact on lipolysis in vivo (unpublished observation).
Evidence for the second mechanism was based on experiments that CLA increased carnitine palmitoyltransferase activities (mainly CPT1) in muscle (Park et al., 1997) . This is the rate limiting enzyme of fatty acid -oxidation. Significant increase of the muscle CPT activity by CLA indicates that CLA-fed animals use more fat as an energy source compared to control. This was also supported by the fact that CLA increased mRNA of CPT1 (unpublished observation). West et al. (1998) reported that CLA-fed mice had decreased respiratory quotient (RQ), which suggests using more fat as an energy source compared to control animals. In addition, CLA has been reported to increase energy expenditure without increasing uncoupling protein gene expression, which is an important mediator of overall energy metabolism and energy expenditure (West et al., 2000) . However, Muller et al. (1998 Muller et al. ( , 2000 reported no effect on RQ or energy metabolism in CLA fed pigs.
CLA and Stearoyl-CoA Desaturase
CLA consistently alters the cell membrane fatty acid composition by reducing the levels of monounsaturated fatty acids, thus CLA decreases the 9 desaturation index (the ratio of palmitoleate/palmitate and oleate/stearate) (Lee et al., 1998) . A decrease in desaturation index indicates a decrease in stearoyl-CoA desaturase (SCD) activity. A proper ratio of saturated to monounsaturated fatty acids is important in maintaining membrane fluidity and alteration of this ratio can influence a variety of physiological responses including, metabolic rate (Storlien et al., 1991) , insulin sensitivity (Jones et al., 1996) , and obesity (Enser, 1975; Field et al., 1990; Jones et al., 1996; Pan et al., 1994) all of which are influenced by CLA. Indeed, CLA (as mixture of mainly cis-9,trans-11 and trans-10,cis-12 isomers, 40.8-45.7% and 43.5-47 .6%, respectively) inhibited the expression of SCD mRNA in mouse liver as well as in differentiating preadipocytes (Choi et al., 2000; Lee et al., 1998) . Choi et al. (2000) found that continuous treatment of differentiating 3T3-L1 preadipocytes with the trans-10,cis-12 isomer of CLA prevents accumulation of lipid droplets and results in a decrease in SCD mRNA expression, protein levels and enzyme activity. Consistent with the reduction in desaturase activity, the levels of C16:1 and C18:1 monounsaturated fatty acids of cell membrane are also reduced. Since these monounsaturated fatty acids constitute 58% of the fatty acids in fat droplets, in differentiated 3T3-L1 adipocytes and in vivo adipocytes (Kasturi and Joshi, 1982) their reduction leads to the formation of small fat cells with small lipid droplets. Thus, the inhibition of SCD gene expression by the trans-10,cis-12 isomer could explain the role of CLA in body fat reduction.
The mechanism of trans-10,cis-12 action on SCD gene expression would possibly involve decreased SCD mRNA stability/or gene transcription (Ntambi, 1999) but recent studies indicate that the trans-10,cis-12 isomer can exert a direct inhibitory effect on SCD enzyme activity (Bretillon et al., 1999; Choi et al., 2001; Park et al., 2000b) . The inhibitory effect of trans-10,cis-12 on SCD enzyme activity is relatively specific because the cis-9,trans-11 and the trans-9,trans-11 isomers of CLA and other polyunsaturated fatty acids including cis-9,cis-12 octadecadienoic acid, trans-9,cis-12 octadecadienoic acid and linoleic acid had no effect (Table 2 ). Doses as low as 3.125 M trans-10,cis-12 CLA isomer exhibited inhibition of SCD activity (about 18% inhibition). Inhibiting SCD can be achieved by taking CLA supplements, since most of food contains mainly the cis-9,trans-11 isomer of CLA. 
Conclusion
The exact mechanisms by which CLA exerts other biological effects have not been completely elucidated. It is quite possible that different isomers of CLA have different effects. For example, the cis-9,trans-11 isomer of CLA is responsible for growth promotion and the trans-10,cis-12 isomer changes body composition, while both are involved in anticancer activity. The trans-10,cis-12 isomer of CLA may work through multiple mechanisms, such as reducing fat uptake in adipocytes, increasing fatty acid -oxidation in muscle, and inhibiting SCD both by reduction of mRNA and protein and by direct inhibition of enzyme activity.
